All In Biotech

Drug Trial Radar · NCT03722355

Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma

A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma

Last checked: Nov 20, 2026Latest source record: Nov 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 712 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

712

Actual

Start

Nov 9, 1990

Primary completion

Mar 15, 1994

Study completion Oct 18, 2002

Sponsor

Lead sponsor
Radiation Therapy Oncology GroupResearch network
Sponsor type
Research network
First posted
Oct 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hyperfractionated radiation therapy (RT) to 72.0 Gy with BCNU will be compared to conventional radiation therapy to 60.0 Gy with BCNU to determine if hyperfractionated RT can improve the median survival time of adults with supratentorial malignant gliomas.

Conditions

  • Glioma
  • Glioblastoma Multiforme
  • Astrocytoma

Interventions

  • Conventional RTRadiation

    Radiation therapy

  • Hyperfractionated RTRadiation

    Radiation therapy

  • CarmustineDrug

    Chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From randomization to the date of death or last follow up, assessed up to 131 months.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.